BCL9 has also been identified as an oncogene in multiple myeloma where BCL9 is upregulated, and disrupting the β-catenin–BCL9 interaction has been shown to decrease transcription of Wnt target genes in colorectal cancer [52]. This evidence concerns the gene BCL9 and plasma cell myeloma.